Association between diabetes mellitus with metabolic syndrome and diabetic microangiopathy

Experimental and Therapeutic Medicine

Volumn 8, Issue 6, 2014, Pages 1867-1873

  Zhang, Xiaoyan ^a   Cui, Xiaoli ^a   Li, Fenghua ^a   Wang, Shuo ^a   Liu, Xinyu ^a   Hui, Lichao ^a   Song, N ^a   Li, Nannan ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes; Diabetic microangiopathy; Metabolic syndrome

Indexed keywords

ALBUMIN; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME KINETICS; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PREVALENCE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; VERY ELDERLY;

EID: 84908170437     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1992     Document Type: Article

References (35)

1. Pi-Sunyer X: The metabolic syndrome: how to approach differing definitions. Med Clin North Am 91: 1025-1040, 2007.
2. Gluckman PD, Hanson MA, Bateson P, et al: Towards a new developmental synthesis: adaptive developmental plasticity and human disease. Lancet 373: 1654-1657, 2009.
3. Cavali Mde L, Escrivão MA, Brasileiro RS and Taddei JA. Metabolic syndrome: comparison of diagnosis criteria. J Pediatr (Rio J) 86: 325-330, 2010 (In Portuguese).
4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications Report of a WHO consultation, Part 1: Diagnosis and classification of diabetes mellitus[M].WHO:Geneva,1999.
5. MS CDS ref-waiting for it in English
6. Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. [J]. Diabetes, 1983, 32(suppl 2):64-78.
7. Ford ES, Giles WH and Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359, 2002.
8. Hajat C and Shather Z: Prevalence of metabolic syndrome and prediction of diabetes using IDF versus ATPIII criteria in a Middle East population. Diabetes Res Clin Pract 98: 481-486, 2012.
9. Riediger ND and Clara I: Prevalence of metabolic syndrome in the Canadian adult population. CMAJ 183: E1127-E1134, 2011.
10. Jia WP, Xiang KS, Chen L, et al: A comparison of the application of two working definitions of metabolic syndrome in Chinese population. Zhonghua Yi Xue Za Zhi 84: 534-538, 2004.
11. Li R, Lv M, Xiao F, et al: Investigation on the prevalence rate of metabolic syndrome among elderly in 5 Chinese urban communities. Xian Dai Yu Fang Yi Xue: 7: 460-462, 2012
12. Cavali Mde L, Escrivão MA, Brasileiro RS and Taddei JA: Metabolic syndrome: comparison of diagnosis criteria. J Pediatr (Rio J) 86: 325-330, 2010.
13. Martins D, Ani C, Pan D, Ogunyemi O and Norris K: Renal dysfunction, metabolic syndrome and cardiovascular disease mortality. J Nutr Metab 2010: 167162, 2010.
14. Saito I, Iso H, Kokubo Y, Inoue M and Tsugane S: Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J 73: 878-884, 2009.
15. Ginter E and Simko V: Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 771: 35-41, 2012.
16. Li S, Rao X and Tan X. The pathogenesis of diabetic retinopathy and clinical research progress. Bai Qiu En Yi Xue Yuan Xue Bao 9: 118-120, 2011.
17. Chen R and Guan C. Prevalence and risk factors analysis of chronic complications in tie in patients with Type 2 diabetes mellitus. Xin Nao Xue Guan Bing Fang Zhi 11: 429, 2011.
18. McNeill AM, Rosamond WD, Girman CJ, et al: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28: 385-390, 2005.
19. Isomaa B, Henricsson M, Almgren P, et al: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44: 1148-1154, 2001.
20. No authors listed. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study (UKPDS) group. Lancet 352: 837-853, 1998.
21. Lee IT, Chiu YF, Hwu CM, et al: Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardivasc Diabetol 11: 43, 2012.
22. Gallagher EJ, Leroith D and Karnieli E: The metabolic syndrome - from insulin resistance to obesity and diabetes. Med Clin North Am 95: 855-873, 2011.
23. Barth RJ: Insulin resistance, obesity and the metabolic syndrome. S D Med Spec No: 22-27, 2011.
24. No authors listed. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research group. N Engl J Med 329: 977-986, 1993.
25. Duran-Perez EG, Almeda-Valdes P, Cuevas-Ramos D, Campos-Barrera E, Muñoz-Hernandez L and Gomez-Perez FJ: Treatment of metabolic syndrome slows progression of diabetic nephropathy. Metab Syndr Relat Disord 9: 483-489, 2011.
26. Maric C and Hall JE: Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol 170: 28-35, 2011.
27. Thorn LM, Forsblom C, Wadén J, Saraheimo M, Tolonen N, Hietala K and Groop PH; Finnish Diabetic Nephropathy (FinnDiane) Study Group: Metabolic syndrome as a risk factor for cardiovascular disease, mortality and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32: 950-952, 2009.
28. Martínez Castelao A: Advances in diabetes mellitus, diabetic nephropathy, metabolic syndrome and cardio-vascular-renal risk. Nefrologia 28 (Suppl 5): 79-84, 2008 (In Spanish).
29. Raman R, Gupta A, Pal SS, Ganesan S, Venkatesh K, Kulothungan V and Sharma T: Prevalence of Metabolic Syndrome and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 14). Diabetol Metab Syndr 2: 67, 2010.
30. Sass DA, Chang P and Chopra KB: Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 50: 171-180, 2005.
31. Kolovou GD, Anagnostopoulou KK and Cokkinos DV: Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81: 358-366, 2005.
32. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S and Fowler S; Diabetes Prevention Program Research Group: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611-619, 2005.
33. Muzio F, Mondazzi L, Sommariva D and Branchi A: Long-term effects of low-calorie diet on the metabolic syndrome in obese nondiabetic patients. Diabetes Care 28: 1485-1486, 2005.
34. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K and Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690, 2005.
35. Hanford LE, Enghild JJ, Valnickova Z, et al: Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279: 50019-50024, 2004.